An estimated 50% of depressed patients are inadequately treated by available interventions.
Even with an eventual recovery, many patients require a trial and error approach, as there …

Depression is a major cause of disability worldwide, but we know little about the underlying
fundamental biology. Research is hindered by the difficulties of modelling a disorder of …

Advances in characterizing the neuropathology and functional dysconnectivity of depression
and promising trials with emerging circuit-targeted and fast-onset therapeutics are providing …

Major depressive disorder is a heritable psychiatric syndrome that appears to be associated
with subtle cellular and molecular alterations in a complex neural network. The affected …

The search for more effective treatments for depression is a long-standing primary objective
in both psychiatry and translational neuroscience. From initial models centered on …

Major depressive disorder is a remarkably common and often severe psychiatric disorder
associated with high levels of morbidity and mortality. Patients with major depression are …

Since the 1960s, when the first tricyclic and monoamine oxidase inhibitor antidepressant
drugs were introduced, most of the ensuing agents were designed to target similar brain …

Major depression is a leading contributor to the global burden of disease. This situation is
mainly related to the chronicity and/or recurrence of the disorder, and to poor response to …

Depression is a complex, heterogeneous disorder and a leading contributor to the global
burden of disease. Most previous research has focused on individual brain regions and …

Major depressive disorder (MDD) will affect one out of every five people in their lifetime and
is the leading cause of disability worldwide. Nevertheless, mechanisms associated with the …